JPMorgan Starts Cerevel Therapeutics (CERE) at Overweight, Sees 53% Upside
Tweet Send to a Friend
(Updated - January 5, 2022 7:47 AM EST)JPMorgan analyst Cory Kasimov initiated coverage on Cerevel Therapeutics (NASDAQ: CERE) with an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
